FARMACO IN FASE I°
Pain Therapeutics Initiates Clinical Study in Cancer Patients
On Tuesday May 5, 2009, 8:30 am EDT
Buzz up! Print Related
ain Therapeutics Inc.
SAN MATEO, Calif., May 5, 2009 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (NasdaqGM
TIE - News), announced the initiation of another clinical study for PTI-188, an investigational drug intended to treat a lethal form of skin cancer called metastatic melanoma (MM). This study follows the release of promising data in an earlier Phase I study for PTI-188, published at the Meeting of the Society for Nuclear Medicine.
Related Quotes
Symbol Price Change
PTIE 4.36 -0.04
{"s" : "ptie","k" : "c10,l10,p20,t10","o" : "","j" : ""} ``No drug therapy exists today to eliminate this cancer,'' said Remi Barbier, president & chief executive officer of Pain Therapeutics. ``I am encouraged by our progress with PTI-188 and believe earlier results indicate PTI-188 may play a significant role in improving survival for patients with MM.''
About the Study Design
This is an open-label, Phase I, dose-escalation study for PTI-188. The primary objective of this study is to assess the safety, pharmacokinetics and anti-tumor activity of PTI-188 in MM patients. Twelve or more cancer patients with confirmed MM will receive a single intravenous dose of PTI-188. Metastatic tumors will be evaluated at baseline, post-treatment and monthly thereafter until disease progression. Patient enrollment is currently underway in Israel. This study is expected to be completed later this year.